# ENANTA PHARMACEUTICALS INC (ENTA)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ENTA/

- Reporting holders: 3
- Reported value: $42.4K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $21.3K | 1,617 | 0.0% | 7 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $18.8K | 1,424 | 0.0% | 6 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $2.3K | 178 | 0.0% | 13 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 3 | $42.4K |
| Q2 2026 | 125 | $412.2M |
| Q1 2026 | 132 | $339.0M |
| Q4 2025 | 132 | $418.2M |
| Q3 2025 | 122 | $233.3M |
| Q2 2025 | 107 | $139.9M |
| Q1 2025 | 111 | $102.9M |
| Q4 2024 | 106 | $114.6M |
| Q3 2024 | 111 | $222.6M |
| Q2 2024 | 100 | $289.3M |
| Q1 2024 | 107 | $465.6M |
| Q4 2023 | 105 | $201.0M |